Sandbox/AL: Difference between revisions
Line 431: | Line 431: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] 1.5-2 g IV q4h'''''<br> OR <br> ▸ '''''[[Oxacillin]] 1.5-2 g IV q4h''''' <br> OR <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] 1.5-2 g IV q4h'''''<br> OR <br> ▸ '''''[[Oxacillin]] 1.5-2 g IV q4h''''' <br> OR <br> ▸ '''''[[Cefazolin]]''''' 1 g IV q8h | ||
▸ '''''[[Cefazolin]]''''' 1 g IV q8h | |||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Dicloxacillin]] 500 mg PO q6h'''' <br> OR <br> ▸ '''''[[Cephalexin]] 500 mg PO q6h''''' <br> OR <br> ▸ '''''[[Clindamycin]] 300 mg PO q8h''''' <br> OR <br> ▸ '''''[[TMP-SMX]] 160-800 mg PO q12h''''' | ||
|- | |- | ||
|} | |} | ||
Line 447: | Line 446: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Preferred Regimen | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] 1.5-2 g IV q4h'''''<br> OR <br> ▸ '''''[[Oxacillin]] 1.5-2 g IV q4h''''' <br> OR <br> ▸ '''''[[Cefazolin]]''''' 1 g IV q8h | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Alternative Regimen <br> Methicillin-resistant | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15-20 mg/kg IV q8h'''''|} | ||
|} | |||
|} | |} | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table14" style="background: #FFFFFF;" | {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table14" style="background: #FFFFFF;" |
Revision as of 15:15, 19 May 2014
The treatment for septic arthritis requires an adequate drainage of purulent joint fluid and appropriate antimicrobial therapy. Empiric therapy should be started after the collection joint fluid and blood sample, and these should be send for culture.
Empiric Therapy Adapted from Lancet 375:846, 2010. [1]
▸ Click on the following categories to expand treatment regimens.
▸ Pediatric ▸ Newborns (< 1 week) ▸ Newborns (1 -4 week) ▸ Infants (1 - 3 months) ▸ Children (3 mo - 14 yr) ▸ Adults ▸ Acute Monoarticular ▸ Chronic Monoarticular ▸ Polyarticular |
|
CSF Gram Stain-Based Therapy Adapted from
▸ Click on the following categories to expand treatment regimens.
Gram-Positive ▸ Gram-Positive Cocci Gram-Negative ▸ Gram-Negative Cocci ▸ Gram-Negative Rods ▸ Negative Gram Stain |
|
Pathogen-Based Therapy — Bacteria Adapted from
▸ Click on the following categories to expand treatment regimens.
Bacteria ▸ Staphylococcus aureus ▸ Staphylococcus epidermidis ▸ Methicillin-resistant S. aureus ▸ Streptococcus groups A, B, C, G ▸ Enterococcus feacalis ▸ Pseudomonas aeruginosa ▸ Neisseria gonorrhoeae ▸ Haemophilus influenzae ▸ Mycobacterium tuberculosis ▸ Borrelia burgdorferi ▸ Treponema pallidum ▸ T. whipplei ▸ Nocardia |
Pathogen-Based Therapy — Fungi▸ Click on the following categories to expand treatment regimens.
Pathogen-Based Therapy in Patients with Prosthetic Joint — Bacteria Adapted from Diagnosis and Management of Prosthetic Joint Infection CID 2013:56[2]▸ Click on the following categories to expand treatment regimens.
|
- ↑ . doi:10.1016/S0140-6736(09)61595-6. Check
|doi=
value (help). Missing or empty|title=
(help) - ↑ Osmon, D. R.; Berbari, E. F.; Berendt, A. R.; Lew, D.; Zimmerli, W.; Steckelberg, J. M.; Rao, N.; Hanssen, A.; Wilson, W. R. (2012). "Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America". Clinical Infectious Diseases. 56 (1): e1–e25. doi:10.1093/cid/cis803. ISSN 1058-4838.